Translational Immunotherapy Team
Institut Curie
INSERM U932
Hopital 2e étage
26 rue d'Ulm
75248 Paris Cedex 05
Lab Website:
Research Interests:
Only a fraction of patients responds to immunotherapies, and many develop resistance. Thus, we need to gain knowledge on the mechanism of action of immunotherapies, identify biomarkers of response and toxicity, and design combinatory therapies, with the final aim of implementing more effective and patient-tailored therapies.
In this context, our research is oriented to identify novel immunological targets and biomarkers in the tumor microenvironment (TME), tumor draining lymph nodes (LNs) and blood of patients, understand their role in the anti-tumor immune response and finally translate our discoveries to patients.
We have set up a standardized procedure for clinical studies, including the collection of blood, LN and tumor samples from patients undergoing surgery. We have implemented multiomix techniques, including multiparametric flow cytometry, single cell RNAseq+TCRseq and ATACseq, CRISPR/CAS9 gene editing, TCR cloning and transduction, syngeneic and humanized mouse models.
Our research program is structured around two main themes:
- Optimization of anti-tumor immune responses in rhabdoïd tumors
- Mechanisms of human Treg development and function in cancer
